Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

"IMPORT FOR EXPORT" PROVISIONS OF EXPORT LAW MAY BE EXPANDED TO INCLUDE UNAPPROVED FINISHED DEVICES; "TRANSSHIPMENT" OF EXPORTS ALSO MAY BE ADDRESSED

This article was originally published in The Gray Sheet

Executive Summary

Congress may expand the "import for export" provisions of "The FDA Export Reform and Enhancement Act of 1996" to allow importation into the U.S. of unapproved finished devices intended for subsequent export, congressional staffers told attendees at a June 27 Food and Drug Law Institute conference in Washington, D.C. The current provisions, which were signed into law April 26, allow manufacturers to import unapproved "components" for assembly of finished devices meant for export.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT006263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel